Loading...
•
Apr 02, 2021
Danaher Q1 2021 Earnings Report
Danaher's Q1 2021 earnings were reported, demonstrating significant year-over-year growth driven by strong core revenue and contributions to COVID-19 related products.
Key Takeaways
Danaher reported a strong start to 2021 with better-than-expected Q1 results. Revenues increased by 58.0% year-over-year to $6.9 billion, with a 30.0% non-GAAP core revenue growth. Net earnings were $1.7 billion, or $2.29 per diluted common share, a 182.5% increase year-over-year. The company anticipates strong non-GAAP core revenue growth for Q2 and the full year 2021.
Revenues increased 58.0% year-over-year to $6.9 billion.
Net earnings were $1.7 billion, or $2.29 per diluted common share, a 182.5% increase year-over-year.
Non-GAAP adjusted diluted net earnings per common share were $2.52, a 140.0% increase over the comparable 2020 period.
Operating cash flow was $1.9 billion, and non-GAAP free cash flow was $1.6 billion, representing increases of 126.5% and 135.0% year-over-year, respectively.
Forward Guidance
The Company anticipates that non-GAAP core revenue growth will be in the mid-20 percent range for the second quarter 2021. For the full year 2021, the Company now anticipates that the non-GAAP core revenue growth rate including Cytiva will be in the high-teens percent range.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...